Essential Premium

Private Deals Fuel Viking’s Standout Funds

In the third quarter, the strategy continued to power the Tiger Cub.

Icahn’s Private Portfolio Lags Market Again, Poised for Another Annual Loss

The legendary investor’s private portfolio fell behind the S&P 500 by nearly 30 percentage points through September.

Sponsored

How Fed Policy Can Impact Corporate Bond Spreads

RTW and Rivals Cash In as Biopharma Roars Back

FDA leadership changes, consolidation, and new product launches have fueled a biotech rally, turning life sciences hedge funds into standout performers.

Related Content

Why the Emperors Have No Clothes

Riva Atlas

Hedgies Take Sides in the Icahn-Buffett-Occidental Battle

Michelle Celarier

The 41% Man

Amanda Cantrell

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram